Hebei General Hospital, Shijiazhuang, Hebei, PR China.
North China University of Science and Technology, Tangshan, Hebei, PR China.
Medicine (Baltimore). 2022 Apr 22;101(16):e28969. doi: 10.1097/MD.0000000000028969.
The prognostic value of SPRY4-Intronic transcript 1 (SPRY4-IT1) in women suffering from breast carcinoma and malignant tumors of the reproductive system remains to be ascertained. Therefore, this paper attempted to assess the relationship between SPRY4-IT1 with the clinicopathological indicators and survival analysis in women suffering from breast carcinoma and malignant tumors of their reproductive organs through meta-analysis.
Related literature retrieved from Cochrane Library, Ovid, Embase, PubMed, the CNKI, and the Web of Science databases were reviewed. The latest article search was updated to September 1, 2021. The outcome indicators included as effective measures in the study were hazard ratio (HR), odds ratio (OR), and 95% confidence interval (CI). The Stata 12.0 software was used to analyze the data.
The elevated SPRY4-IT1 levels were indicative of poor overall survival (OS) [HR = 2.44, 95% CI = 1.35-4.43, P < .05], and were not related to Disease-Free Survival (DFS) [HR = 1.61, 95% CI = 0.50-5.18, P = .43] in female patients suffering from malignant tumors. In terms of lymph node metastasis (LNM) for the association between long noncoding RNA SPRY4-IT1(LncRNA SPRY4-IT1) and OS, elevated LncRNA SPRY4-IT1 implied poor OS with LNM [HR = 2.79, 95% CI: 1.81-4.28, P < .001]. Based on the aspect of the LNM for the association between LncRNA SPRY4-IT1 and DFS, SPRY4-IT1 was not correlated with DFS [HR = 0.97, 95% CI: 0.73-1.28, P = .81]. SPRY4-IT1 in the TNM stage was not related to OS [HR = 1.43, 95% CI: 0.55-3.70, P = .46]. In the TNM stage, SPRY4-IT1 was not related to DFS [HR = 1.68, 95% CI: 0.92-3.06, P = .09]. SPRY4-IT1 was found to be associated with lymph node metastasis (OR = 4.15, 95% CI: 2.75-6.25, P = .000) and TNM stage (OR = 2.89, 95% CI: 1.51-7.27 P = .02). No significant correlation was noted between SPRY4-IT1 and the age of the patients (OR = 0.89, 95% CI: 0.61-1.29 P = .54).
Thus, this study provides evidence-based medical evidence for the target treatment of female breast carcinoma and malignant tumors of the reproductive system. The elevated level of SPRY4-IT1 was associated with poor prognosis of female breast cancer patients and of those having malignant tumors in their reproductive organs. In addition, the SPRY4-IT1 expression was also associated with the disease progression and metastasis.
SPRY4-内含子转录本 1（SPRY4-IT1）在患有乳腺癌和生殖系统恶性肿瘤的女性患者中的预后价值仍有待确定。因此，本研究通过荟萃分析试图评估 SPRY4-IT1 与女性乳腺癌和生殖器官恶性肿瘤患者的临床病理指标和生存分析之间的关系。
检索 Cochrane 图书馆、Ovid、Embase、PubMed、中国知网和 Web of Science 数据库中的相关文献。最新文章搜索更新至 2021 年 9 月 1 日。结果指标包括研究中作为有效措施的风险比（HR）、比值比（OR）和 95%置信区间（CI）。使用 Stata 12.0 软件进行数据分析。
SPRY4-IT1 水平升高与女性恶性肿瘤患者的总生存期（OS）不良相关[HR=2.44，95%CI=1.35-4.43，P<.05]，但与无病生存期（DFS）无关[HR=1.61，95%CI=0.50-5.18，P=0.43]。在淋巴结转移（LNM）方面，长链非编码 RNA SPRY4-IT1（LncRNA SPRY4-IT1）与 OS 的关系中，LncRNA SPRY4-IT1 水平升高与 OS 不良相关[HR=2.79，95%CI：1.81-4.28，P<.001]。基于 LNM 方面，LncRNA SPRY4-IT1 与 DFS 的关系，SPRY4-IT1 与 DFS 无关[HR=0.97，95%CI：0.73-1.28，P=0.81]。TNM 分期的 SPRY4-IT1 与 OS 无关[HR=1.43，95%CI：0.55-3.70，P=0.46]。在 TNM 分期中，SPRY4-IT1 与 DFS 无关[HR=1.68，95%CI：0.92-3.06，P=0.09]。SPRY4-IT1 与淋巴结转移（OR=4.15，95%CI：2.75-6.25，P=0.000）和 TNM 分期（OR=2.89，95%CI：1.51-7.27，P=0.02）有关。SPRY4-IT1 与患者年龄无显著相关性（OR=0.89，95%CI：0.61-1.29，P=0.54）。
综上所述，本研究为女性乳腺癌和生殖系统恶性肿瘤的靶向治疗提供了循证医学证据。SPRY4-IT1 水平升高与女性乳腺癌患者和生殖系统恶性肿瘤患者的预后不良有关。此外，SPRY4-IT1 的表达还与疾病进展和转移有关。
